International Journal of Medical Sciences

Impact factor
2.399

22 October 2017

ISSN 1449-1907 News feeds of published articles

My Manuscript | My Account

Journal of Genomics now in PubMed/PubMed Central. Submit manuscript...

Journal of Biomedicinenew

Theranostics

Journal of Cancer

Oncomedicine

International Journal of Biological Sciences

Journal of Genomics

Journal of Bone and Joint Infection (JBJI)

Nanotheranostics

PubMed Central Indexed in Journal Impact Factor

Int J Med Sci 2008; 5(2):87-91. doi:10.7150/ijms.5.87

Research Paper

TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders

Jan Palmblad1, Magnus Björkholm2, Jack Kutti3, Gerd Lärfars4, Eva Löfvenberg1, Berit Markevärn5, Mats Merup1, Nils Mauritzson6, Jan Westin6, Jan Samuelsson4, Gunnar Birgegård7

1. Hematology Center, Karolinska University Hospital Huddinge, Stockholm
2. Hematology Center, Karolinska University Hospital Solna, Stockholm
3. Dept of Hematology, Sahlgrenska University Hospital, Göteborg
4. Dept of Medicine, Stockholm South Hospital, Stockholm
5. Dept of Medicine, University Hospital, Umeå
6. Dept of Hematology, University Hospital, Lund, Sweden
7. Dept of Medicine, University Hospital, Uppsala, for the Swedish MPD Study Group.

Abstract

Anagrelide is often used in the treatment of thrombocythemia in myeloproliferative disease (MPD), but information concerning effects of treatment on cytokines involved in regulation of blood platelet levels is limited. Here, we investigated serum levels of thrombopoietin (TPO) and soluble IL-6 receptor (sIL-6R) in relation to response to treatment with and plasma concentrations of anagrelide. Samples from 45 patients with thrombocythemia due to MPD (ET=31, PV=14), being treated with anagrelide for 6 months, were analyzed for TPO, sIL-6R and anagrelide levels. The mean baseline platelet count was 983x109/L. A reduction of platelets to <600 in asymptomatic or <400 x 109/L in symptomatic patients was defined as a complete remission (CR), a reduction with >50% of baseline as partial remission, and <50% reduction as failure. At 6 months, 35 patients were in CR, 1 had a partial remission and 9 were treatment failures. For all patients, there was an increase in TPO of 44% from baseline; this change was more pronounced for patients with partial remission and failure. sIL-6R levels did not change significantly. There was no correlation between levels of anagrelide and cytokine levels at 6 months, and changes of cytokine levels did not relate to changes of platelet counts. Thus, a pronounced increase of TPO levels after 6 months of anagrelide treatment indicated that this treatment affected a major regulatory mechanism for megakaryocyte and platelet formation in MPD.

Keywords: thrombocythemia, anagrelide, thrombopoietin, IL-6, soluble receptors

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Palmblad J, Björkholm M, Kutti J, Lärfars G, Löfvenberg E, Markevärn B, Merup M, Mauritzson N, Westin J, Samuelsson J, Birgegård G. TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders. Int J Med Sci 2008; 5(2):87-91. doi:10.7150/ijms.5.87. Available from http://www.medsci.org/v05p0087.htm